Johnson & Johnson (JNJ US)
JNJ US$271.04
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 271.04
- Change
- ▲ 2.31 (0.86)
- Bid / Ask
- 271.22 - 271.24
- Volume
- 1,780,999
- Turnover
- 419,837,217
- Open
- 265.63
- Day Range
- 264.50 - 272.75
- VWAP
- 270.82
- Prev Close
- 268.73
- Last Trade
- 28/10 4:10pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 2,409,898,597
- NTA/Share
- -7.32
- Last Dividend
- 1.34
- Dividend Ex Date
- 25 AUG 2026
- Dividend Pay Date
- 8 SEP 2026
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 94,193.00
- EBITDA
- 39,999.00
- Profit
- 26,804.00
- Earnings Per Share (EPS)
- 11.03
- Dividend Per Share (DPS)
- 5.14
- Yield %
- 2.05
- Market Cap
- 652,477.37
- Price to Earnings Ratio (P/E)
- 41.19
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 108,164.40
- EBITDA
- 40,231.72
- Profit
- 29,624.07
- Earnings Per Share (EPS)
- 12.02
- Dividend Per Share (DPS)
- 5.57
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Overvalued
- Economic Moat
- Wide
- Financial Health
- Strong
- Uncertainty
- High
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 196.73 Fair value 232.92 One-star price 275.78
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 232.92
- Price / Fair Value
- 1.11
- Valuation
- Overvalued
- Uncertainty
- High
Morningstar Quantitative Rating as of 21 OCT 2026. The slider runs from the five-star price (196.73) to the one-star price (275.78).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 257.78 |
| Price - 12 month high | 281.00 |
| Price - 12 month low | 184.67 |
| Pricing date | 20 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 7.96 |
| Market capitalization | 620,556.44 |
| 12 Month High price date | 2 SEP 2026 |
| 12 Month Low price date | 29 OCT 2025 |
| Volume - avg. trading volume for the last 3 months | 7.07 |
| Price - 1 Day % Change | -0.61% |
| Price - 13 week price percent change | 2.86% |
| Price - 26 week price percent change | 13.98% |
| Price - 5 Day % Change | 1.52% |
| Price - 52 week price percent change | 34.34% |
| Price - YTD price percent change | 24.59% |
| Price % Change Month To Date | -4.34% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 11.030 |
| EPS excluding extraordinary items - trailing 12 month | 6.590 |
| EPS Normalized - most recent fiscal year | 10.790 |
| Revenue/share - most recent fiscal year | 38.772 |
| Revenue/share - trailing 12 month | 40.625 |
| Book value per share - most recent fiscal year | 33.865 |
| Book value per share - most recent quarter | 33.870 |
| Book value (tangible) per share - most recent fiscal year | -7.322 |
| Book value (tangible) per share - most recent quarter | -5.649 |
| Cash per share - most recent fiscal year | 8.185 |
| Cash per share - most recent quarter | 7.025 |
| Cash Flow per share - most recent fiscal year | 15.332 |
| Cash Flow per share - trailing 12 month | 8.801 |
| Dividend per share - most recent fiscal year | 5.140 |
| Dividends per share - trailing 12 month | 5.280 |
| EBITD per share - trailing 12 month | 10.609 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 11.130 |
| EPS Basic excluding extraordinary items - trailing 12 month | 6.680 |
| EPS including extraordinary items - most recent fiscal year | 11.130 |
| EPS including extraordinary items - trailing 12 month | 6.680 |
| Free Cash Flow per share - trailing 12 month | 6.117 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 39.12 |
| P/E Normalized, most recent fiscal year | 24.20 |
| Price to sales - most recent fiscal year | 6.35 |
| Price to Tangible Book - most fiscal year | — |
| Price to Free Cash Flow per Share - most recent fiscal year | 42.14 |
| Price to Cash Flow per share - trailing 12 month | 29.29 |
| Price to Book - most recent fiscal year | 7.61 |
| P/E excluding extraordinary items high, trailing 12 months | 39.36 |
| P/E excluding extraordinary items low, trailing 12 months | 17.97 |
| Net Debt, LFI | 27,423.00 |
| Net Debt, LFY | 27,831.00 |
| Dividend Yield - 5 Year Average | 2.68% |
| Dividend Yield - indicated annual dividend divided by closing price | 2.04% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 2.05% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 32,031.00 |
| LT debt/equity - most recent fiscal year | 48.36% |
| Payout ratio - most recent fiscal year | 46.60% |
| Total debt/total equity - most recent fiscal year | 58.78% |
| LT debt/equity - most recent quarter | 43.91% |
| Total debt/total equity - most recent quarter | 54.77% |
| Free Cash Flow - trailing 12 month | 14,956.00 |
| Payout ratio - trailing 12 month | 80.24% |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 94,193.00 |
| Revenue - trailing 12 month | 99,335.00 |
| EBITD - most recent fiscal year | 39,999.00 |
| EBITD - trailing 12 month | 25,941.00 |
| Earnings before taxes - most recent fiscal year | 32,581.00 |
| Earnings before taxes - trailing 12 month | 17,737.00 |
| Net Income available to common - most recent fiscal year | 26,804.00 |
| Net Income available to common - trailing 12 months | 16,095.00 |
| Earnings before taxes Normalized - most recent fiscal year | 27,985.00 |
| Net Income Available to Common, Normalized - most recent fiscal year | 26,215.00 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 10.65 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 28.46% |
| Net Profit Margin % - trailing 12 month | 16.20% |
| Operating margin - 1st historical fiscal year | 27.17% |
| Operating margin - trailing 12 month | 25.70% |
| Pretax margin - trailing 12 month | 17.86% |
| Pretax margin - 1st historical fiscal year | 34.59% |
| Operating Margin - 5 year average | 25.96% |
| Pretax Margin - 5 year average | 23.92% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 24.87% |
| Free Operating Cash Flow/Revenue, TTM | 15.06% |
| Net Profit Margin - 5 year average | 20.60% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 13.97% |
| Return on average assets - trailing 12 month | 8.12% |
| Return on average equity - most recent fiscal year | 34.46% |
| Return on average equity - trailing 12 month | 19.70% |
| Return on average assets - 5 year average | 9.46% |
| Return on average equity - 5 year average | 23.42% |
| Net Income/employee - most recent fiscal year | 193,950.80 |
| Revenue/employee - most recent fiscal year | 681,570.19 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 2.67% |
| EPS growth rate, 5 year | 14.89% |
| Growth rate% - dividend, 3 year | 4.92% |
| Revenue/share (5 yr growth) | 4.63% |
| Growth rate% - Revenue, 3 year | 5.60% |
| Growth rate% - EPS, 3 year | 17.90% |
| Book value per share growth rate, 5 year | 7.10% |
| Capital Spending growth rate, 5 year | 9.28% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 10.92% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
